Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Public ClinicalTrials.gov record NCT06305754. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).
Study identification
- NCT ID
- NCT06305754
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 551 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab tirumotecan Biological
- Pemetrexed Drug
- Carboplatin Drug
- H1 Receptor Antagonist Drug
- H2 Receptor Antagonist Drug
- Acetaminophen (or equivalent) Drug
- Dexamethasone (or equivalent) Drug
- Steroid Mouthwash (dexamethasone or equivalent) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2024
- Primary completion
- Aug 16, 2028
- Completion
- Jun 13, 2030
- Last update posted
- Aug 2, 2026
2024 – 2030
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente - Oakland ( Site 0054) | Oakland | California | 94611 | — |
| Kaiser Permanente - Roseville ( Site 0055) | Roseville | California | 95661 | — |
| Kaiser Permanente - San Francisco ( Site 0056) | San Francisco | California | 94115 | — |
| Kaiser Permanente - Santa Clara ( Site 0057) | Santa Clara | California | 95051 | — |
| Kaiser Permanente-Kaiser Permanente ( Site 0036) | Vallejo | California | 94589 | — |
| Kaiser Permanente - Walnut Creek ( Site 0058) | Walnut Creek | California | 94596 | — |
| Mid Florida Hematology and Oncology Center ( Site 0005) | Orange City | Florida | 32763 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) | Marietta | Georgia | 30060 | — |
| University of Michigan ( Site 0009) | Ann Arbor | Michigan | 48109 | — |
| Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051) | Springfield | Missouri | 65807 | — |
| Astera Cancer Care ( Site 0032) | East Brunswick | New Jersey | 08816 | — |
| Stony Brook University-Cancer Center ( Site 0038) | Stony Brook | New York | 11794 | — |
| Sanford Fargo Medical Center ( Site 0028) | Fargo | North Dakota | 58122 | — |
| Sanford Cancer Center ( Site 0024) | Sioux Falls | South Dakota | 57104 | — |
| John Peter Smith Hospital ( Site 0065) | Fort Worth | Texas | 76104 | — |
| University of Texas MD Anderson ( Site 0063) | Houston | Texas | 77030 | — |
| Millennium Research & Clinical Development ( Site 0035) | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06305754, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06305754 live on ClinicalTrials.gov.